Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gusacitinib - Asana BioSciences

Drug Profile

Gusacitinib - Asana BioSciences

Alternative Names: ASN002

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asana BioSciences
  • Class Acetonitriles; Antineoplastics; Antirheumatics; Piperidines; Pyridazines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Chronic lymphocytic leukaemia; Dermatitis; Myelofibrosis; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 14 Aug 2019 Asana BioSciences completes the phase II RADIANT trial in Atopic dermatitis in USA, Canada and Germany (NCT03531957)
  • 28 Jul 2019 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
  • 03 Jan 2019 Phase-II clinical trials in Dermatitis (In adults, In the elderly) in Canada, USA (PO) (NCT03728504)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top